Study design
This single-center, prospective, randomized clinical trial was conducted between December 2018 and June 2021. All measurements (visual field, optic disc imaging, and IOP) were made by research team members masked to treatment allocation. Clinicians and patients were not masked in treatment allocation. Using a web-based system, we randomly assigned patients (1:1) to either SLT or 0.005% latanoprost as first-line treatment (